Semmaphorin 3 A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8⁺ T cells

Area of Science:

• Immunology
• Cancer Biology
• Cellular Signaling

Background:

• Semaphorin-3A (SEMA3A) is a known chemorepulsive signal impacting T cell function.
• The precise mechanisms by which SEMA3A affects tumor-specific T cells remain unclear.
• Understanding SEMA3A's role is crucial for developing effective cancer immunotherapies.

Purpose of the Study:

• To investigate the role of Semaphorin-3A (SEMA3A) in regulating CD8+ T cell infiltration into tumors.
• To determine the molecular interactions between SEMA3A, its receptors (Neuropilin-1/Plexins), and T cell function.
• To evaluate the therapeutic potential of targeting the SEMA3A pathway in cancer.

Main Methods:

• Analysis of Neuropilin-1 (NRP1) and Plexin receptor expression on stimulated CD8+ T cells.
• In vivo studies involving genetic deletion or overexpression of NRP1 and SEMA3A in tumor models.
• Assessment of T cell migration, immunological synapse formation, and filamentous actin (F-actin) dynamics.
• Correlation of SEMA3A expression with patient survival in clear cell renal cell carcinoma.

Main Results:

• NRP1, Plexin-A1, and Plexin-A4 are upregulated on stimulated CD8+ T cells.
• Tumor-derived SEMA3A inhibits T cell migration and immunological synapse assembly by affecting F-actin.
• NRP1 deletion in T cells enhances tumor infiltration and restricts tumor growth.
• SEMA3A overexpression inhibits CD8+ T cell infiltration.
• High SEMA3A expression in clear cell renal cell carcinoma correlates with reduced patient survival.

Conclusions:

• SEMA3A acts as a significant inhibitor of effector CD8+ T cell infiltration into tumors.
• The SEMA3A/NRP1 axis disrupts T cell motility and immune synapse formation.
• Targeting NRP1 represents a promising strategy to enhance anti-tumor T cell responses.